MedTrace Logo

Long-term Follow-up Study of BRL-101 for TDT

NCT06298630 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-03-22

No results posted yet for this study

Summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Conditions

  • Thalassemia, Beta

Interventions

OTHER

Assessments

Safety and efficacy assessments

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

    collaborator OTHER

  • Shenzhen Children 's Hospital

    collaborator UNKNOWN

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • Xiaochen Wang · Bioray Laboratories

Eligibility

Min Age
3 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-08
Primary Completion
2038-08-20
Completion
2038-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06298630 on ClinicalTrials.gov